Ovid Therapeutics Q2 net loss $12.4M; OV329 SAD complete; Graviton ROCK2 collaboration

Ovid Therapeutics Inc.

2023-Q2 EPS reported -$0.37 revenue$222,600,000

Cash and securities $96.5M as of June 30, 2023; net loss $0.18 per share vs $0.21 year ago.
OV329 Phase 1 single-ascending-dose portion completed with no safety signals; full data expected H1 2024.
Entered license/collaboration with Graviton for ROCK2 inhibitors with $10M equity investment.
Appointed Dr. Zhong Zhong CSO and Dr. Manoj Malhotra CMO; Meg Alexander promoted to Chief Strategy Officer.
Implemented cost-cutting measures including G&A headcount reduction; cash runway expected into 2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Ovid Therapeutics Inc. reported financial results for second quarter ended June 30, 2023.

Period: second quarter ended June 30, 2023
Result: reported results

Exact text from the filing

On August 4, 2023, Ovid Therapeutics Inc. (the “Company”) issued a press release announcing Second Quarter 2023 Financial Results and Corporate Updates.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Ovid Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-027426

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.